Trulicity, Byetta, Victoza, Similar Diabetes Drugs Do Not Appear to Increase Breast Cancer Risks: Study
Pancreatic Cancer Lawsuits Over Byetta, Victoza and Other Diabetes Drugs Won’t Be Selected For Bellwether Trials Until Late 2020
Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
AstraZeneca Buys Bristol-Myers Squibb Diabetes Interests, Byetta February 11, 2014 Irvin Jackson Add Your Comments Amid a mounting number of Byetta lawsuits and other claims by former users who allege they developed cancer after taking Bristol-Myers Squibb diabetes medications, the drug maker has decided to sell off its entire diabetes division to AstraZeneca.  Last week, AstraZeneca announced that it will pay $4.1 billion to acquire Bristol-Myers Squibb’s diabetes drug line, including Byetta, Bydureon, Onglyza, Kombiglyze XR, Komboglyze, dapagliflozin, Xigduo, metreleptin and Symlin. The sale means that about 4,100 employees will switch companies. The acquisition comes as a number product liability lawsuits have been filed nationwide involving some Bristol-Myers Squibb diabetes drugs that are part of a class of medications known as incretin mimetics. The complaints allege that former users of Byetta, Bydureon and Onglyza developed pancreatic cancer or thyroid cancer after using the drugs. Learn More About Byetta Lawsuit Side effects of Byetta, Victoza, Januvia and other diabetes drugs may increase risk of pancreatic cancer. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Byetta Lawsuit Side effects of Byetta, Victoza, Januvia and other diabetes drugs may increase risk of pancreatic cancer. Learn More SEE IF YOU QUALIFY FOR COMPENSATION There are currently dozens of Byetta pancreatic cancer and thyroid cancer cases pending throughout the country, claiming that inadequate warnings were provided for consumers and the medical community about the potential side effects of the medication. Bydureon is a longer-acting version of Byetta, which has also been implicated in several lawsuits. There are also a growing number of Onglyza lawsuits filed that involve allegations that plaintiffs developed pancreatic cancer. As part of the deal to acquire the Bristol-Myers diabetes division, AstraZeneca paid out an initial $2.7 billion, plus another $1.4 billion in payments for sales, regulatory costs and launch fees. Another $600 million in royalties will be paid until 2025, and AstraZeneca may pay another $225 million for some of Bristol-Myers Squibb’s assets. Incretin Mimetic Cancer Concerns Byetta (exenatide) was the first member of the incretin mimetic class of diabetes drugs, which was introduced by Amylin Pharmaceuticals in 2005 as a twice daily injection. Bydureon (exenatide extended-release) was introduced by Amylin in January 2012, as a once-weekly injection. Amylin was then acquired by Bristol-Myers Squibb in July 2012, for $5.3 billion. Onglyza (saxagliptin) is an oral medication that is part of the same class of diabetes drugs, which was approved by the FDA in July 2009. This medication was jointly co-developed by Bristol-Myers Squbb and AstraZeneca as a competitor for Amylin’s Byetta and Merck’s popular Januvia and Janumet drugs, which are also oral incretin mimetic drugs. Incretin mimetics work by work by mimicking the incretin hormones that the body usually produces to naturally stimulate the release of insulin in response to a meal. However, over the past year, concerns have been raised about the risk users may face of developing cancer following long-term use of the medications. In February 2013, researchers from Johns Hopkins in Baltimore found that taking Januvia or Byetta may double the risk of hospitalization due to pancreatitis, which experts indicated may lead some users to develop pancreatic cancer over time. In March 2013, the risk of pancreatic cancer from Januvia, Byetta and other incretin mimetics gained additional attention, after a study published in the medical journal Diabetes found that pancreas tissue from organ donars found that those who took an incretin mimetic were more likely to have increased pancreatic mass and precancerous cells, which are cells with the potential to evolve into tumors. Most recently, a study was published late last year by Italian researchers indicated that a review of 1,169 adverse drug reaction reports identified at least 90 cases of users of incretin mimetics suffering from pancreatitis and elevated pancreatic enzymes. Acute or chronic pancreatitis can lead to the development of pancreatic cancer. Diabetes Drug Litigation As the number of complaints began to spike throughout the federal court system, the U.S. Judicial Panel on Multidistrict Litigation (JPML) established coordinated proceedings in the federal court system in August 2013. All pancreatic cancer lawsuits involving Januvia, Janumet, Byetta and Victoza are currently consolidated as part of an MDL, or Multidistrict Litigation, which is centralized before U.S. District Judge Anthony J. Battalglia in the Southern District of California to reduce duplicative discover, avoid conflicting pretrial rulings from different judges and to serve the convenience of the parties, witnesses and the courts. At this time, the MDL is limited to just cases against the makers of Byetta, Januvia, Janumet and Victoza for plaintiffs who allege they developed pancreatic cancer. However, the scope of the litigation is expanding. Last month, a motion was filed with the U.S. JPML asking that several dozen Byetta thyroid cancers lawsuits be centralized before Judge Battaglia. According to the request, there are currently at least 36 complaints pending in three different U.S. District Courts, and the cases involve common questions of fact and law with the pancreatic cancer lawsuits, justifying the centralization of the cases before the same judge. During a status conference before Judge Battaglia on January 16, the parties also reported that there are a growing number of Onglyza pancreatic cancer lawsuits filed against AstraZeneca and Bristol-Myers Squibb. Judge Battaglia indicated that the Court will discuss whether these cases will be joined with the incretin mimetic MDL during a future status conference. Tags: AstraZeneca, Bristol Myer Squibb, Bydureon, Byetta, Diabetes, Diabetes Drugs, Onglyza, Pancreatic Cancer More Byetta Lawsuit Stories Trulicity, Byetta, Victoza, Similar Diabetes Drugs Do Not Appear to Increase Breast Cancer Risks: Study March 25, 2021 Pancreatic Cancer Lawsuits Over Byetta, Victoza and Other Diabetes Drugs Won’t Be Selected For Bellwether Trials Until Late 2020 December 30, 2019 Januvia Pancreatic Cancer Lawsuit To Be Decided By Jury, Illinois Appeals Court Determines January 2, 2019 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermPhoneThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: 3 days ago) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025) Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor (Posted: 4 days ago) As new Depo-Provera lawsuits continue to be filed, the judge presiding over the litigation has established key criteria for establishing proof of Depo-Provera use and medical documentation confirming a meningioma diagnosis. MORE ABOUT: DEPO-PROVERA LAWSUITDepo Shot Lawsuit Filed Over Serious Brain Tumor Injuries (05/07/2025)Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (05/01/2025)Depo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025) BioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (Posted: 5 days ago) A Massachusetts woman’s injuries from a failed tissue marker that was recently recalled led to the need for physical therapy, according to a BioZorb implant lawsuit. MORE ABOUT: BIOZORB LAWSUITFour Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025)Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (04/02/2025)
Trulicity, Byetta, Victoza, Similar Diabetes Drugs Do Not Appear to Increase Breast Cancer Risks: Study March 25, 2021
Pancreatic Cancer Lawsuits Over Byetta, Victoza and Other Diabetes Drugs Won’t Be Selected For Bellwether Trials Until Late 2020 December 30, 2019
Januvia Pancreatic Cancer Lawsuit To Be Decided By Jury, Illinois Appeals Court Determines January 2, 2019
MDL Judge Orders Paraquat Lawsuit Settlement Update By June 11, 2025 (Posted: 3 days ago) A federal judge has agreed to stay all case-specific discovery deadlines in Paraquat lawsuits, while the parties work to hammer out a settlement agreement to resolve thousands of claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSParaquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (04/16/2025)Appeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)
Court Outlines Requirements for Depo-Provera Lawsuit Proof of Use, Type of Meningioma Tumor (Posted: 4 days ago) As new Depo-Provera lawsuits continue to be filed, the judge presiding over the litigation has established key criteria for establishing proof of Depo-Provera use and medical documentation confirming a meningioma diagnosis. MORE ABOUT: DEPO-PROVERA LAWSUITDepo Shot Lawsuit Filed Over Serious Brain Tumor Injuries (05/07/2025)Lawsuit Alleges Depo-Provera Migraines, Headaches Led to Meningioma Brain Tumor Diagnosis (05/01/2025)Depo-Provera Hearing Loss Lawsuit Filed Over Brain Tumor Side Effects (04/22/2025)
BioZorb Implant Lawsuit Alleges Tissue Marker Caused Swelling, Fluid Buildup and Chronic Pain (Posted: 5 days ago) A Massachusetts woman’s injuries from a failed tissue marker that was recently recalled led to the need for physical therapy, according to a BioZorb implant lawsuit. MORE ABOUT: BIOZORB LAWSUITFour Women File BioZorb Lawsuit Over Breast Tissue Marker Failures and Injuries (05/05/2025)Lawsuit Claims BioZorb Marker Caused Chronic Pain, Multiple Surgeries After Lumpectomy (04/14/2025)Four BioZorb Breast Tissue Marker Lawsuits Selected for Bellwether Trials (04/02/2025)